glp-1 intestinal paralysis lawyer in louisiana Ozempic What You Need to Know
Description
What does this mean for weight loss companies
Altimmune just made a big move in the world of GLP-1 research, but this time, its not about obesity.The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD
The 13 states that maintain coverage impose strict restrictions including BMI thresholds over 30, prior authorization requirements, and step therapy mandating patients first try diet, exercise, and cheaper alternatives
Consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without T2D
Experts say more education and awareness are needed.
A 43% lower risk of metastatic breast cancer progression in GLP-1 users at ASCO 2026 (hazard ratio 0.57)
